Eric Koegle Email & Phone Number

Hickory, North Carolina, United States

Responsible for all aspects of Pharmacy Operations within the store including inventory, personnel and security with emphasis on customer relations. Service and satisfy the customer/s as health care needs in and out of Pharmacy area.Openly communicate with customers / patients while protecting their confidential health and drug information; to provide counsel to customers having medical questions.Solicit information on a customer/s medical history to give appropriate medical advice.Maintain inventory levels by following defined ordering practices for warehouse and approved outside vendors using the Telxon machine.Utilize drug usage report to adjust shelf order bases.Maintain a perpetual schedule II inventory.Comply to all security / Loss Prevention procedures including setting alarm; secure safe.Provide a performance review and evaluation of subordinate staff at least on an annual basis.Coach and execute counseling discussions with technicians.Total store scheduling with store manager.Participate in total store operational meetings.Access, input and retrieve information from the computer.Operate a cash register – including: cash, check and charge transactions; bagging merchandise.Obtain needed information for new prescriptions and refills via telephone.Fill prescriptions (product selection; counting and measuring drugs; capping and uncapping vials and bottles; labeling of prescriptions) and prepare compounds.Check-in, price and put away all drug orders – in including CIIs.Retrieve and file prescriptions in the appropriate files (including CIIs).Pull outdated, damaged and recalled merchandise and prepare for return.Complete Third Party rejections.Maintain: daily and weekly reports.In cases of dispensing incidents, follow company procedures: notification, report completion.Communicate and interact with physicians, dentists, nurses and others in health related fields to better serve our customer.

Charlotte, North Carolina Area

Assisted with the CVS acquisition of multiple Target pharmacies and trained pharmacists on workflow, inventory and the Rx Connect system.

Taussig Cancer Center

Previously conducted research in the laboratory of clinical pharmacology within the Experimental Therapeutics Program now known as the Department of Translational Hematologic and Oncologic Research (THOR) of the Taussig Cancer Institute. Previously worked with ovarian, endometrial, lung, leukemia, and renal cell carcinomas examining drug sensitivity in order to maximize efficacy and reduce toxicity of cancer chemotherapy. Currently modifying Topoisomerase enzymes and transfecting them to cells then determining the biological effect of the modification. Performing western blotting and real-time PCR analysis to assess the molecular effect of the transformation. Through modification of these topoisomerase enzymes we determine its regulatory effect during cell growth and differentiation. Through the studies with topoisomerase II, we have determined multiple defective phosphorylation sites that cancer cells use as a mechanism to evade chemotherapy. Using engineered model systems, we are learning to understand how addition of phosphate at specific sites makes this enzyme vulnerable to drug therapy in order to develop novel treatment strategies. I am part of the research team that submitted the following abstracts for the American Association of Cancer Researchers (AACR): Tyrosine phosphorylation of RIN1 modulates the anti-proliferative effects of sorafenib and sunitinib in renal cell carcinoma (RCC) (2010) and Over-expression of cisplatin resistance-associated over expression protein (CROP) is correlated with platinum resistance in ovarian cancer (2009).

Taussig Cancer Center

Previously conducted research in the laboratory of clinical pharmacology within the Experimental Therapeutics Program now known as the Department of Translational Hematologic and Oncologic Research (THOR) of the Taussig Cancer Institute. Previously worked with ovarian, endometrial, lung, leukemia, and renal cell carcinomas examining drug sensitivity in order to maximize efficacy and reduce toxicity of cancer chemotherapy. Currently modifying Topoisomerase enzymes and transfecting them to cells then determining the biological effect of the modification. Performing western blotting and real-time PCR analysis to assess the molecular effect of the transformation. Through modification of these topoisomerase enzymes we determine its regulatory effect during cell growth and differentiation. Through the studies with topoisomerase II, we have determined multiple defective phosphorylation sites that cancer cells use as a mechanism to evade chemotherapy. Using engineered model systems, we are learning to understand how addition of phosphate at specific sites makes this enzyme vulnerable to drug therapy in order to develop novel treatment strategies. I am part of the research team that submitted the following abstracts for the American Association of Cancer Researchers (AACR): Tyrosine phosphorylation of RIN1 modulates the anti-proliferative effects of sorafenib and sunitinib in renal cell carcinoma (RCC) (2010) and Over-expression of cisplatin resistance-associated over expression protein (CROP) is correlated with platinum resistance in ovarian cancer (2009).

Department Of Pharmacology

Familiar with two types of human breast cancer cell lines, MCF-7 and NCI-ADR, human ovarian lymphoma cells HeLa and also murine macrophage cells J774-A1. Performed various cell viability assays with novel anti-cancer agents, mainly aza-anthrapyrazole compounds with tertiary amine side chains. Cells were then dosed at various concentrations and different time points and observed using fluorescence microscopy. Localization, distribution and excretion of the drug was determined and hypotheses were created on how cell lines work to eliminate drug and evade cancer chemotherapy.

Department Of Pharmacology

Observed developmental oxidative stress in the zebrafish HSP-eGFP (Danio rerio) model system. The zebrafish was genetically modified to emit green fluorescence in areas of oxidative stress under ultraviolet light. Examined the developmental toxicity using thiomersal, mercury chloride, mercury nitrate, ethanol and various types of nanoparticles such as fullerenes, multi-walled nanotubes, single-walled nanotubes and carbon chains. After dosing the embryos, they were observed using fluorescence microscopy. These genetically engineered fish fluoresced in areas of the central nervous system indicating neurological damage. A paper that came from my research entitled “Developmental Toxicity of Nanoparticles in the Zebrafish, Danio rerio” was presented at the first International Conference on Nanotoxicology: Biomedical Aspects.

Doctor Of Pharmacy (Pharm.D.), Doctorate Of Pharmacy

Master Of Science (Ms) In Pharmaceutical Sciences, Pharmacology And Toxicology

Dissertation: “Determining the Intracellular Localization and Efficacy of Novel Anticancer Agents in Human Breast Cancer Cell Lines.

Bachelor Of Pharmacy (Bpharm) In Pharmaceutical Sciences, Pharmacology And Toxicology

Thesis: “Developmental Toxicity of Nanoparticles in the Zebrafish, Danio rerio”